Drugs / Olpasiran
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT06411860 | Sep → Nov 2024 | — | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT05481411 | Sep 2022 → Apr 2023 | — | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT05489614 | Sep 2022 → Oct 2023 | impaired renal function disease | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT04987320 | Jul → Nov 2021 | hyperlipoproteinemia | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT03626662 | Jul 2018 → Apr 2023 | cardiovascular disorder | Amgen | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07293260 | Mar 2026 → Jun 2028 expected | cardiovascular disorder | Amgen | Recruiting | No outcome recorded |
| Phase 3 | NCT07136012 | Aug 2025 → Oct 2031 expected | cardiovascular disorder | Amgen | Recruiting | No outcome recorded |
| Phase 3 | NCT05581303 | Dec 2022 → Mar 2028 expected | atherosclerotic cardiovascular disease | Amgen | Active not recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT04270760 Comparator | Jul 2020 → Dec 2021 | cardiovascular disorder | Amgen | Completed | No outcome recorded |
| — | NCT07079267 Background | — | — | Amgen | Available | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2023-08-26 | Amgen | Results AMGEN PRESENTS LATE-BREAKING PHASE 2 OLPASIRAN DATA AT ESC 2023 amgen.com ↗
In the off-treatment extension period, olpasiran showed a lasting effect on Lp(a) reduction nearly a year after the last dose. |
| 2023-03-01 | Amgen | Results AMGEN TO PRESENT NEW REPATHA® (EVOLOCUMAB) AND OLPASIRAN DATA AT ACC amgen.com ↗
Analysis From Phase 2 OCEAN(a)-DOSE Study Shows Olpasiran Markedly Reduced Lp(a) Concentration Irrespective of Baseline Level |
| 2022-11-06 | Amgen | Results AMGEN PRESENTS NEW PHASE 2 DATA THAT SHOW OLPASIRAN DELIVERS SIGNIFICANT REDUCTION IN LIPOPROTEIN(A) LEVELS amgen.com ↗
Patients who received 75 mg or higher every 12 weeks had a 95% or greater reduction in Lp(a) compared to placebo at week 36. |
| 2022-05-31 | Amgen | Results AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 2 DATA FOR INVESTIGATIONAL OLPASIRAN IN ADULTS WITH ELEVATED LIPOPROTEIN(a) amgen.com ↗
Amgen (NASDAQ:AMGN) today announced positive topline data from the Phase 2 OCEAN(a)-DOSE clinical study, evaluating olpasiran (formerly AMG 890) in 281 adult patients with Lipoprotein(a), or Lp(a), levels over 150 nmol/L and evidence of atherosclerotic cardiovascular disease (ASCVD). |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-08-26 | Amgen | AMGEN PRESENTS LATE-BREAKING PHASE 2 OLPASIRAN DATA AT ESC 2023 amgen.com ↗ |
| 2023-03-01 | Amgen | AMGEN TO PRESENT NEW REPATHA® (EVOLOCUMAB) AND OLPASIRAN DATA AT ACC amgen.com ↗ |
| 2022-11-06 | Amgen | AMGEN PRESENTS NEW PHASE 2 DATA THAT SHOW OLPASIRAN DELIVERS SIGNIFICANT REDUCTION IN LIPOPROTEIN(A) LEVELS amgen.com ↗ |
| 2022-05-31 | Amgen | AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 2 DATA FOR INVESTIGATIONAL OLPASIRAN IN ADULTS WITH ELEVATED LIPOPROTEIN(a) amgen.com ↗ |
| 2020-07-29 | Arrowhead Pharmaceuticals | Arrowhead Pharmaceuticals Earns $20 Million Milestone Payment from Amgen for Start of Phase 2 Trial of AMG 890 arrowheadpharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Olpasiran | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07136012 ↗ |
| Known as | AMG 890 | “A Randomized, Placebo- and Positive-controlled, Crossover Study to Assess the Effect of Olpasiran (AMG 890) on QT/QTc Intervals in Healthy Subjects” NCT06411860 ↗ |
| Route | Subcutaneous | “olpasiran administered subcutaneously (SC)” NCT04270760 ↗ |